Eli Lilly price target raised to $985 from $925 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Eli Lilly (LLY) to $985 from $925 and keeps an Overweight rating on the shares. Eli Lilly’s results highlighted strong underlying demand for tirzepatide, with global volume growth outpacing modest pricing pressures and reflecting solid commercial execution, the analyst tells investors in a research note. Previously cited overhangs, including drug policy and competitive pricing concerns, appear largely priced in, Cantor says, adding that upcoming catalysts, including eloranlutide updates, retatrutide pivotal data, and the orforglipron filing, could drive further multiple expansion as Lilly strengthens its leadership in diabetes and obesity.